These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 21740381

  • 1. RNA interference and amyotrophic lateral sclerosis.
    Rizvanov AA, Gulluoglu S, Yalvaç ME, Palotás A, Islamov RR.
    Curr Drug Metab; 2011 Sep; 12(7):679-83. PubMed ID: 21740381
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. RNA interference protects against ALS in mouse model.
    Burton A.
    Lancet Neurol; 2005 May; 4(5):274-5. PubMed ID: 15861555
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis.
    Ding H, Schwarz DS, Keene A, Affar el B, Fenton L, Xia X, Shi Y, Zamore PD, Xu Z.
    Aging Cell; 2003 Aug; 2(4):209-17. PubMed ID: 12934714
    [Abstract] [Full Text] [Related]

  • 7. Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis.
    Kaur SJ, McKeown SR, Rashid S.
    Gene; 2016 Feb 15; 577(2):109-18. PubMed ID: 26657039
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS).
    Abati E, Bresolin N, Comi G, Corti S.
    Expert Opin Ther Targets; 2020 Apr 15; 24(4):295-310. PubMed ID: 32125907
    [Abstract] [Full Text] [Related]

  • 10. SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS.
    Hayashi Y, Homma K, Ichijo H.
    Adv Biol Regul; 2016 Jan 15; 60():95-104. PubMed ID: 26563614
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Current developments in gene therapy for amyotrophic lateral sclerosis.
    Scarrott JM, Herranz-Martín S, Alrafiah AR, Shaw PJ, Azzouz M.
    Expert Opin Biol Ther; 2015 Jul 15; 15(7):935-47. PubMed ID: 25959569
    [Abstract] [Full Text] [Related]

  • 13. [Gene therapy of ALS with RNA interference].
    Yokota T.
    Rinsho Shinkeigaku; 2009 Nov 15; 49(11):821-3. PubMed ID: 20030220
    [Abstract] [Full Text] [Related]

  • 14. Silencing strategies for therapy of SOD1-mediated ALS.
    van Zundert B, Brown RH.
    Neurosci Lett; 2017 Jan 01; 636():32-39. PubMed ID: 27507699
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis.
    Nizzardo M, Simone C, Falcone M, Riboldi G, Rizzo F, Magri F, Bresolin N, Comi GP, Corti S.
    Cell Mol Life Sci; 2012 May 01; 69(10):1641-50. PubMed ID: 22094924
    [Abstract] [Full Text] [Related]

  • 17. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.
    Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, Kwong LK, Forman MS, Ravits J, Stewart H, Eisen A, McClusky L, Kretzschmar HA, Monoranu CM, Highley JR, Kirby J, Siddique T, Shaw PJ, Lee VM, Trojanowski JQ.
    Ann Neurol; 2007 May 01; 61(5):427-34. PubMed ID: 17469116
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.